Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) will host a conference call at 5:00 p.m. ET on Thursday, February 12, 2026 to discuss fourth-quarter and full-year 2025 financial results and a corporate update. A live webcast and replay will be available via the company investor website.
The replay will remain available for three months following the call.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
On the day this news was published, RARE gained 3.83%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RARE slipped 0.44% while peers were mixed: TLX up 0.85%, XENE, NAMS, SLNO, and SRRK down between 1.17% and 4.55%, suggesting stock-specific trading rather than a unified sector move.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 28 | Earnings call scheduling | Neutral | -0.5% | Announced Q3 2025 results call and webcast access details. |
| Jul 30 | Earnings call scheduling | Neutral | -1.9% | Scheduled Q2 2025 conference call to review financials and updates. |
| Apr 30 | Earnings call scheduling | Neutral | -0.0% | Set date and time for Q1 2025 financial results call. |
| Feb 06 | Earnings call scheduling | Neutral | -0.9% | Announced Q4 and full-year 2024 results conference call. |
| Oct 29 | Earnings call scheduling | Neutral | -1.8% | Planned Q3 2024 financial results and corporate update call. |
Similar conference-call announcements over the past five quarters saw small, mostly negative price moves, averaging -1.04% on the day of announcement.
Over the past year, Ultragenyx has regularly issued releases announcing quarterly and annual earnings conference calls, including events on Oct 29, 2024, Feb 6, 2025, Apr 30, 2025, Jul 30, 2025, and Oct 28, 2025. Each notice provided timing, coverage period, and webcast access details, with replays available for three months. These announcements were followed by modest share-price moves, generally slightly negative, indicating that such scheduling updates have historically been low-impact information events.
Historical Comparison
Past five earnings-call scheduling releases moved RARE by an average of -1.04%. Today’s modest -0.44% pre-call move sits within that historical range.
The company has maintained a consistent pattern of quarterly earnings conference calls, providing structured updates on financial performance and corporate progress for each reporting period.
Market Pulse Summary
This announcement schedules Ultragenyx’s fourth quarter and full-year 2025 results call for February 12, 2026 at 5:00 p.m. ET, with a replay available for three months. Similar calls have been held regularly each quarter, providing updates on financial performance and pipeline progress. In light of recent preliminary 2025 figures and regulatory filings, investors may focus on finalized revenue, cash metrics, and any updated timelines for key gene therapy programs.
AI-generated analysis. Not financial advice.
NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 12, 2026, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2025.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
FAQ
When is Ultragenyx (RARE) holding its Q4 and FY2025 financial results call?
How can investors listen to Ultragenyx (RARE) earnings call and where is the replay available?
What topics will Ultragenyx (RARE) discuss on the February 12, 2026 call?
Will the Ultragenyx (RARE) earnings call include a replay and how long will it remain available?
Where is the Ultragenyx (RARE) webcast hosted and is prior registration required?
